GlassScriptPhysician profile
Amy M Hernandez
NPI 1609279298
$1,254.27
in general payments reported to CMS, 2019-2025
23 companies · $256 in 2025
The $256 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $171 · 2022: $101 · 2023: $418 · 2024: $308 · 2025: $256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $966 · Education: $16.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $966.49 |
| Education | $16.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $249.84 | 2021-2025 | Evenity, Prolia, Krystexxa |
| Abbvie INC. | $216.35 | 2021-2025 | |
| Tersera Therapeutics LLC | $79.61 | 2023-2024 | Quzyttir |
| Gilead Sciences, INC. | $72.66 | 2023-2024 | |
| Melinta Therapeutics, LLC | $71.81 | 2023-2024 | Orbactiv, Kimyrsa, Rezzayo |
| Merck Sharp & Dohme LLC | $51.15 | 2023-2025 | Zerbaxa, Dificid, Recarbrio |
| Nestle Healthcare Nutrition INC. | $49.65 | 2023 | |
| Smith+Nephew, INC. | $40.71 | 2022 | |
| Shionogi INC | $40.63 | 2022 | |
| Insmed, INC. | $39.47 | 2023-2024 | Arikayce |
| Octapharma USA, INC. | $38.49 | 2023 | Panzyga |
| Viiv Healthcare Company | $38.19 | 2025 | Dovato |
| Organon LLC | $32.89 | 2024 | |
| Pfizer INC. | $30.70 | 2023-2025 | |
| Theratechnologies INC. | $30.16 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $24.84 | 2024 | |
| Ferring Pharmaceuticals INC. | $24.44 | 2024 | Rebyota |
| Daiichi Sankyo INC. | $22.87 | 2021 | |
| Pharmacosmos Therapeutics INC. | $21.47 | 2023 | Monoferric |
| Ucb, INC. | $21.40 | 2025 | Bimzelx |
| Sandoz INC. | $21.19 | 2023 | Hyrimoz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.46 | 2023 | Cyltezo |
| Celgene Corporation | $15.29 | 2024 | Orencia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Hernandez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.